Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Phase 2
Active, not recruiting
NCT06502977
| Condition | Extensive Stage Small Cell Lung Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Amgen |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 32 participants |
|---|
| Interventions | Tarlatamab |
|---|
| Start date | Aug 27, 2024 |
|---|
| Completion date | Mar 28, 2025 |
|---|
| Results posted | Apr 15, 2026 |
|---|
Summary
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
From first dose of trial drug up to a minimum of last dose + 65 days or data cutoff date; median (min, max) time on trial was 3.4 (2.2, 6.5) months at data cut off · percentage of participants
| Tarlatamab | 38.7 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.